Sleeping Sickness

CHA

Tag: Sleeping Sickness

Breakthrough Sleeping Sickness Drug Approved for DNDi

Recommendation based on Phase II/III study demonstrating up to 96 per cent success rates at 18 months across both early and advanced stages of T.b. gambiense, the most common form of sleeping sicknessThe therapy, given as a single dose of...

Read more
Show Buttons
Share On Facebook
Share On Twitter
Share On Linkedin
Contact us
Hide Buttons